Biotechnology company Avidity Biosciences, Inc. (RNA) surged 6.7% in early trading after announcing the completion of pricing for a $600 million equity offering aimed at advancing its clinical programs and expanding commercial infrastructure. The proceeds will be utilized to support the development of its AOC platform and potential product commercialization, establishing a foundation for the company's future growth.